GE Healthcare Technologies Inc. (GEHC)

In July 2025, GE HealthCare announced a cash dividend for the second quarter and the FDA approved expanded indications for GE HealthCare's Vizamyl PET Imaging Agent. In May 2025, UBS upgraded its outlook for GE HealthCare Technologies from Sell to Neutral. In April 2025, GEHC reported Q1 2025 earnings per share (EPS) of $1.01, beating estimates, but lowered its full-year Adjusted EPS guidance due to an estimated negative impact from incremental tariffs. In March 2025, Goldman Sachs upgraded its outlook for GE HealthCare Technologies from Neutral to Buy. In January 2025, GE HealthCare was named to the 2025 Fortune World's Most Admired Companies™ list and entered a multi-year strategic partnership with Sutter Health. As of July 14, 2025, the stock price was $74.45 per share, representing a decline of 7.16% from July 15, 2024. As of July 18, 2025, the share price was $75.96, an increase of 1.10% from the previous day. The company's market capitalization as of July 16, 2025, was $34.55 billion.

GE HealthCare's demand is influenced by factors such as increased elective procedures in the US and Canada. The company has seen robust demand in the U.S. and EMEA markets, while demand in China has experienced a drop. The company's organic orders growth was robust, up 10% year-over-year in Q1 2025. Approximately half of GE Healthcare's revenue is recurring, consisting of servicing, pharmaceutical diagnostics, and digital solutions. The company's sales are geographically diverse, which can help mitigate risks associated with regional demand fluctuations.

GE Healthcare Technologies, Inc. (GEHC) is a global medical technology, pharmaceutical diagnostics, and digital solutions company operating in the healthcare sector. The company's business model is diversified and caters to healthcare providers worldwide. Its core business segments include Medical Imaging Solutions, which offers advanced imaging equipment; Advanced Visualization Solutions (AVS), which provides tools that enhance the clarity and detail of imaging data; Patient Care Solutions (PCS), which delivers products designed to monitor, manage, and improve patient outcomes; and Pharmaceutical Diagnostics (PDx), which supplies diagnostic solutions for pharmaceutical analysis and testing. Approximately half of GE Healthcare's revenue comes from equipment sales, with the other half from consumables and services.

GE Healthcare Technologies Inc. operates in a diverse and globally dispersed market, with sales and service operations spanning multiple regions. The company operates in more than 100 countries. In 2023, 42% of its revenue came from the United States and 13% from China. Major regional operations are located in Buc (France), Helsinki (Finland), Kraków (Poland), Budapest (Hungary), Yizhuang (China), Hino & Tokyo (Japan), and Bangalore (India), with its largest R&D center in Bangalore.

GE HealthCare was named to the 2025 Fortune World's Most Admired Companies™ list on January 29, 2025. This recognition highlights the company's progress in its precision care strategy, innovation, quality of management, products and services, value as a long-term investment, financial soundness, talent acquisition and retention, community and environmental responsibility, global business, and use of corporate assets.

GE HealthCare Technologies Inc. has 2,197 institutional owners and shareholders holding a total of 494,653,131 shares. Approximately 61.99% of the company's stock is owned by institutional investors, 0.23% by insiders, and 37.78% by public companies and individual investors. The largest institutional shareholders include Vanguard Group Inc., Capital Research Global Investors and BlackRock, Inc. The Vanguard Group, Inc. is the largest shareholder with 11% of shares outstanding.